跳至主要内容
临床试验/IRCT2015090621315N2
IRCT2015090621315N2已完成3 期

A randomized, double blind clinical trial to evaluate biosafety of trastuzumab produced by aryogen company (™Hercease) in comparison to Roche company trastuzumab (™Herceptin)

Aryogene pharmed company0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 70 years(—)
性别
Female

入选标准

  • inclusion criteria: female aged 18- 70 years at the time of signing the informed consent form; HER2+ breast cancer in ich experiment with 3+ and or 2+ that has reported positive by FISH method; ECOG grade between 0-1; LVEF 55% or more.
  • exclusion criteria: bilateral metastatic breast cancer; other malignancies; renal, liver, bone marrow and cardiac insufficiencies; hypertention; pregnancy or planning to be pregnant.

排除标准

  • 未提供

研究者

发起方
Aryogene pharmed company

相似试验